vs
ANI PHARMACEUTICALS INC（ANIP）とRibbon Communications Inc.（RBBN）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $162.6M、Ribbon Communications Inc.の約1.5倍）。Ribbon Communications Inc.の純利益率が高く（54.8% vs 11.1%、差は43.6%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -10.3%）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -8.1%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Ribbon Communications Inc.は通信事業者、企業、重要インフラ分野に向け、ソフトウェア、IPおよび光ネットワークソリューションを提供する企業です。2017年にGenbandとSonus Networksが合併して設立され、本社は米国テキサス州プレイノに置かれている上場企業です。
ANIP vs RBBN — 直接比較
損益計算書 — Q4 FY2025 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $162.6M |
| 純利益 | $27.5M | $89.1M |
| 粗利率 | — | 42.9% |
| 営業利益率 | 14.1% | 37.6% |
| 純利益率 | 11.1% | 54.8% |
| 売上前年比 | 29.6% | -10.3% |
| 純利益前年比 | 367.5% | — |
| EPS（希薄化後） | $1.14 | $0.50 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | — | $162.6M | ||
| Q4 25 | $247.1M | $227.3M | ||
| Q3 25 | $227.8M | $215.4M | ||
| Q2 25 | $211.4M | $220.6M | ||
| Q1 25 | $197.1M | $181.3M | ||
| Q4 24 | $190.6M | $251.4M | ||
| Q3 24 | $148.3M | $210.2M | ||
| Q2 24 | $138.0M | $192.6M |
| Q1 26 | — | $89.1M | ||
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-12.1M | ||
| Q2 25 | $8.5M | $-11.1M | ||
| Q1 25 | $15.7M | $-26.2M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $-13.4M | ||
| Q2 24 | $-2.3M | $-16.8M |
| Q1 26 | — | 42.9% | ||
| Q4 25 | — | 53.3% | ||
| Q3 25 | — | 50.1% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 45.4% | ||
| Q4 24 | — | 55.7% | ||
| Q3 24 | — | 52.1% | ||
| Q2 24 | — | 50.8% |
| Q1 26 | — | 37.6% | ||
| Q4 25 | 14.1% | 4.1% | ||
| Q3 25 | 15.9% | 1.3% | ||
| Q2 25 | 6.6% | 1.9% | ||
| Q1 25 | 13.3% | -10.8% | ||
| Q4 24 | -2.3% | 13.2% | ||
| Q3 24 | -13.8% | -0.4% | ||
| Q2 24 | 3.7% | -1.0% |
| Q1 26 | — | 54.8% | ||
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -5.6% | ||
| Q2 25 | 4.0% | -5.0% | ||
| Q1 25 | 8.0% | -14.5% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | -6.4% | ||
| Q2 24 | -1.7% | -8.7% |
| Q1 26 | — | $0.50 | ||
| Q4 25 | $1.14 | $0.50 | ||
| Q3 25 | $1.13 | $-0.07 | ||
| Q2 25 | $0.36 | $-0.06 | ||
| Q1 25 | $0.69 | $-0.15 | ||
| Q4 24 | $-0.45 | $0.05 | ||
| Q3 24 | $-1.27 | $-0.08 | ||
| Q2 24 | $-0.14 | $-0.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $67.6M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $419.1M |
| 総資産 | $1.4B | — |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $67.6M | ||
| Q4 25 | $285.6M | $96.4M | ||
| Q3 25 | $262.6M | $74.8M | ||
| Q2 25 | $217.8M | $60.5M | ||
| Q1 25 | $149.8M | $71.2M | ||
| Q4 24 | $144.9M | $87.8M | ||
| Q3 24 | $145.0M | $37.2M | ||
| Q2 24 | $240.1M | $64.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $342.1M | ||
| Q3 25 | — | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
| Q1 26 | — | $419.1M | ||
| Q4 25 | $540.7M | $449.0M | ||
| Q3 25 | $505.8M | $360.1M | ||
| Q2 25 | $436.8M | $370.4M | ||
| Q1 25 | $418.6M | $381.8M | ||
| Q4 24 | $403.7M | $404.6M | ||
| Q3 24 | $405.9M | $395.5M | ||
| Q2 24 | $455.8M | $405.0M |
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.1B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | — |
| FCFマージンFCF / 売上 | 11.8% | — |
| 設備投資強度設備投資 / 売上 | 0.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.10× | — |
| 直近12ヶ月FCF直近4四半期 | $171.4M | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $29.2M | ||
| Q3 25 | $44.1M | $26.5M | ||
| Q2 25 | $75.8M | $-795.0K | ||
| Q1 25 | $35.0M | $-3.5M | ||
| Q4 24 | $15.9M | $61.8M | ||
| Q3 24 | $12.5M | $-14.8M | ||
| Q2 24 | $17.4M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $27.3M | ||
| Q3 25 | $38.0M | $21.0M | ||
| Q2 25 | $71.8M | $-6.5M | ||
| Q1 25 | $32.5M | $-15.7M | ||
| Q4 24 | $13.5M | $53.8M | ||
| Q3 24 | $7.7M | $-23.7M | ||
| Q2 24 | $13.0M | $-12.9M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 12.0% | ||
| Q3 25 | 16.7% | 9.7% | ||
| Q2 25 | 34.0% | -2.9% | ||
| Q1 25 | 16.5% | -8.7% | ||
| Q4 24 | 7.1% | 21.4% | ||
| Q3 24 | 5.2% | -11.3% | ||
| Q2 24 | 9.4% | -6.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 0.9% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 1.3% | 6.7% | ||
| Q4 24 | 1.3% | 3.2% | ||
| Q3 24 | 3.2% | 4.2% | ||
| Q2 24 | 3.2% | 1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
